Annovis has secured U.S. Patent No. 12,582,632 B2, which encompasses both the prevention and treatment of neurological injuries stemming from brain infections through the administration of buntanetap and related compounds. This patent includes claims for its use in healthy individuals at risk of exposure to infectious agents and for the reversal of neurological damage in affected patients, with protection extending through 2044. Buntanetap is currently in Phase 3 clinical trials and is designed as a once-daily oral therapy that targets the overproduction of neurotoxic aggregating proteins, such as amyloid-beta and tau.

The significance of this patent lies in its broad applicability against various infectious agents known to contribute to neurological damage. Annovis cites pathogens linked to Alzheimer’s disease, including herpes simplex virus, HIV, COVID-19, and bacteria associated with Lyme disease and periodontal infections. By addressing these pathogens, the therapeutic potential of buntanetap may extend beyond traditional neurodegenerative diseases, potentially offering a novel approach to mitigate neurological injuries caused by infections, which is an area of growing concern in both clinical and research settings.

This development shifts the current research paradigm by highlighting the intersection of infectious disease and neurodegeneration. It opens avenues for further exploration into how infectious agents contribute to neurological decline and suggests that therapeutic strategies like buntanetap could play a crucial role in both prevention and treatment. As a result, this patent may influence drug development timelines, encouraging more focused research on the implications of infectious agents in neurological health and the potential for repurposing existing compounds for broader therapeutic applications.

Source: longevity.technology